Results of a randomized, double-blind, placebo-controlled clinical study are said to indicate that ENI’s patented whole grape extract may increase HDL-cholesterol and decrease the ratio of total cholesterol to HDL-cholesterol in people with pre-hypertension, overweight, and/or pre-diabetes.
Cal Bewicke, President of ENI, said the study “scientifically validates the health benefits associated with products concentrated from whole grapes”.
Bewicke told NutraIngredients-USA that the trial data has been submitted for publication in peer reviewed journal. NutraIngredients-USA has not seen the full data.
The US Patent and Trademark Office granted a patent in 2011 to ENI for the ingredient (U.S. Patent 7,959,963), and the ingredient is patent-pending in China and the European Union, said ENI. It is marketed under the brand names ORAC-15M and VinCare and it is standardized to contain 80% grape polyphenols with an ORAC Value of 15,000 micromolesTE/gram. The branded ingredients are GRAS affirmed, added the company.
In addition to the potential cholesterol benefits, six weeks of supplementation with the ingredient at a dose of 350 milligrams per day was also associated with improvements in key biomarkers reflecting oxidative stress, such as 8-isoprostane levels.